Tag: Stiripentol

In 2018, the U.S. Food and Drug Administration (FDA) approved stiripentol, marketed under the brand name Diacomit, for treating seizures associated with Dravet syndrome. This milestone confirmed that **is stiripentol available in the USA** for this specific, rare form of epilepsy.

Dravet syndrome is a rare form of epilepsy with an incidence of 1 per 20,000 to 40,000 births. So, what is the generic name for the drug stiripentol, a key medication used to manage it?

According to the manufacturer, Biocodex, DIACOMIT (stiripentol) is an orphan medicinal product and is distributed exclusively through a specialty pharmacy, confirming it is a specialty drug. This classification significantly impacts how the medication is accessed and managed for patients with Dravet syndrome.

DIACOMIT (stiripentol) is an anticonvulsant approved by the FDA for the treatment of seizures associated with Dravet syndrome. Specifically, it is used as an adjunctive, or add-on, therapy with clobazam to help manage the frequent and prolonged seizures that are characteristic of this rare and severe form of epilepsy.

According to a pooled analysis of pivotal trials, stiripentol significantly reduced convulsive seizure frequency in up to 70% of patients with Dravet syndrome. So, **what is the drug stiripentol used for**? It is prescribed as an adjunctive treatment for seizures associated with this severe, genetic epilepsy.